Subacute inflammatory demyelinating polyneuropathy in children.
Reported are five children with subacute demyelinating polyneuropathy. All patients had a monophasic disease, progressing over 4 to 8 weeks and characterized by predominantly motor features, areflexia, minimal or no cranial nerve abnormalities, no autonomic or respiratory involvement, elevated CSF protein, electrophysiologic evidence of demyelination, and good response to corticosteroids. A benign course with full recovery was the rule.
Rodriguez-Casero
M Victoria
MV
Department of Neurology, Royal Children's Hospital, Parkville, Victoria, Australia.
Shield
Lloyd K
LK
Kornberg
Andrew J
AJ
D000293:Adolescent; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease / Q000145:classification; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009046:Motor Neurons / Q000502:physiology; D018908:Muscle Weakness / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000294:innervation / Q000473:pathology / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D010291:Paresis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D010525:Peripheral Nerves / Q000473:pathology / Q000503:physiopathology*; D011129:Polyradiculoneuropathy / Q000145:classification / Q000175:diagnosis* / Q000503:physiopathology*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000145:classification / Q000175:diagnosis* / Q000503:physiopathology*; D011239:Prednisolone / Q000008:administration & dosage; D012021:Reflex, Abnormal / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D011239:Prednisolone